A case of advanced gastric cancer responding to paclitaxel/CDDP neoadjuvant chemotherapy leading to pathologically complete response

A 74-year-old male with advanced gastric cancer(cT3N1M0H0P0CY0, cStage III A)was treated with paclitaxel/ CDDP as neoadjuvant chemotherapy. Paclitaxel (80 mg/m(2)) and CDDP (25 mg/m(2)) were administered on days 1, 8 and 15 as one cycle. After the second course, a significant tumor reduction was obt...

Full description

Saved in:
Bibliographic Details
Published inGan to kagaku ryoho Vol. 35; no. 8; p. 1383
Main Authors Sakon, Masahiro, Sekino, Yasushi, Okita, Kouichi, Kusama, Kei, Seki, Hitoshi, Munakata, Yasuhiro, Hosaka, Noriko, Mikami, Kazuhisa
Format Journal Article
LanguageJapanese
Published Japan 01.08.2008
Subjects
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cisplatin - therapeutic use
Endoscopes, Gastrointestinal
Gastrectomy
Humans
Male
Neoadjuvant Therapy
Neoplasm Staging
Paclitaxel - therapeutic use
Stomach Neoplasms - diagnostic imaging
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Stomach Neoplasms - surgery
Tomography, X-Ray Computed
Online AccessGet more information

Cover

More Information
Summary:A 74-year-old male with advanced gastric cancer(cT3N1M0H0P0CY0, cStage III A)was treated with paclitaxel/ CDDP as neoadjuvant chemotherapy. Paclitaxel (80 mg/m(2)) and CDDP (25 mg/m(2)) were administered on days 1, 8 and 15 as one cycle. After the second course, a significant tumor reduction was obtained. Total gastrectomy, splenectomy, and D2 type nodal dissection were performed. The histological diagnosis revealed complete disappearance of cancer cells in the stomach and all of the lymph nodes, a so-called pathologically complete response. The patient has now been in good health without any recurrence for 9 months after surgery. This case suggests that neoadjuvant chemotherapy with paclitaxel/CDDP is a potential regimen for advanced gastric cancer.
ISSN:0385-0684